{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:56:01Z","timestamp":1760100961445,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T00:00:00Z","timestamp":1487376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00277-017-2943-8","type":"journal-article","created":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T10:48:10Z","timestamp":1487414890000},"page":"757-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-\u03b1 therapy"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-0473","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Jud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen S.","family":"Goede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Senn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Spanaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Benz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,18]]},"reference":[{"key":"2943_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"19","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 19:5019\u20135032","journal-title":"Blood"},{"key":"2943_CR2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","volume":"13","author":"BA Bouroncle","year":"1958","unstructured":"Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609\u2013630","journal-title":"Blood"},{"key":"2943_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R et al (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 105:1684\u20131692","journal-title":"Br J Cancer"},{"key":"2943_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","volume":"115","author":"MR Grever","year":"2010","unstructured":"Grever MR (2010) How I treat hairy cell leukemia. Blood 115:21\u201328","journal-title":"Blood"},{"key":"2943_CR5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood.V53.3.412.412","volume":"53","author":"BA Bouroncle","year":"1979","unstructured":"Bouroncle BA (1979) Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 53:412\u2013436","journal-title":"Blood"},{"key":"2943_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.2011.08931.x","volume":"156","author":"G Jones","year":"2012","unstructured":"Jones G, Parry-Jones N, Wilkins B et al (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 156:186\u2013195","journal-title":"Br J Haematol"},{"key":"2943_CR7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","volume":"119","author":"L Arcaini","year":"2012","unstructured":"Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188\u2013191","journal-title":"Blood"},{"key":"2943_CR8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bjh.12490","volume":"163","author":"R Chandran","year":"2013","unstructured":"Chandran R, Gardiner SK, Smith SD et al (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163:407\u2013409","journal-title":"Br J Haematol"},{"key":"2943_CR9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","volume":"13","author":"M Grever","year":"1995","unstructured":"Grever M, Kopecky K, Foucar MK et al (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974\u2013982","journal-title":"J Clin Oncol"},{"key":"2943_CR10","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1038\/bcj.2014.3","volume":"4","author":"V Maevis","year":"2014","unstructured":"Maevis V, Mey U, Schmidt-Wolf G et al (2014) Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 4:e184","journal-title":"Blood Cancer J"},{"key":"2943_CR11","doi-asserted-by":"crossref","first-page":"v100","DOI":"10.1093\/annonc\/mdv200","volume":"26","author":"T Robak","year":"2015","unstructured":"Robak T, Matutes E, Catovsky D et al (2015) Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v100\u2013v107","journal-title":"Ann Oncol"},{"key":"2943_CR12","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","volume":"127","author":"S Dietrich","year":"2016","unstructured":"Dietrich S, Pircher A, Endris V et al (2016) BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127:2847\u20132855","journal-title":"Blood"},{"key":"2943_CR13","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T et al (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822\u20131828","journal-title":"J Clin Oncol"},{"key":"2943_CR14","doi-asserted-by":"crossref","unstructured":"Nyalakonda H, Utay NS (2015) A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis","DOI":"10.1097\/QCO.0000000000000190"},{"key":"2943_CR15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975\u2013982","journal-title":"N Engl J Med"},{"key":"2943_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399\u2013401","journal-title":"Nature"},{"key":"2943_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10428199209053608","volume":"7","author":"F Lauria","year":"1992","unstructured":"Lauria F, Rondelli D, Raspadori D et al (1992) Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. Leuk Lymphoma 7:103\u2013107","journal-title":"Leuk Lymphoma"},{"key":"2943_CR18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood.V76.10.1941.1941","volume":"76","author":"JM Richards","year":"1990","unstructured":"Richards JM, Mick R, Latta JM et al (1990) Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 76:1941\u20131945","journal-title":"Blood"},{"key":"2943_CR19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0609.2008.01190.x","volume":"82","author":"R Benz","year":"2009","unstructured":"Benz R, Siciliano RD, Stussi G et al (2009) Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol 82:194\u2013200","journal-title":"Eur J Haematol"},{"key":"2943_CR20","doi-asserted-by":"crossref","unstructured":"(2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama ;310:2191\u20132194","DOI":"10.1001\/jama.2013.281053"},{"key":"2943_CR21","volume-title":"Laktat Dehydrogenase (LDH)","author":"USZ","year":"2014","unstructured":"USZ (2014) Laktat Dehydrogenase (LDH). Universit\u00e4tsSpital Z\u00fcrich, Z\u00fcrich"},{"key":"2943_CR22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","volume":"145","author":"M Else","year":"2009","unstructured":"Else M, Dearden CE, Matutes E et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16\u00a0years from diagnosis. Br J Haematol 145:733\u2013740","journal-title":"Br J Haematol"},{"key":"2943_CR23","volume-title":"U.S.Departement of health and human services","author":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2009","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2009) U.S.Departement of health and human services. National Cancer Institute, USA"},{"key":"2943_CR24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-89-5-677","volume":"89","author":"HM Golomb","year":"1978","unstructured":"Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677\u2013683","journal-title":"Ann Intern Med"},{"key":"2943_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0971-5851.144988","volume":"35","author":"V Somasundaram","year":"2014","unstructured":"Somasundaram V, Purohit A, Aggarwal M et al (2014) Hairy cell leukemia: a decade long experience of north Indian hematology center. Indian J Med Paediatr Oncol 35:271\u2013275","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2943_CR26","first-page":"E229","volume":"91","author":"F Bouafia","year":"2004","unstructured":"Bouafia F, Drai J, Bienvenu J et al (2004) Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bull Cancer 91:E229\u2013E240","journal-title":"Bull Cancer"},{"key":"2943_CR27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5858\/2006-130-374-PPPOMR","volume":"130","author":"P Mhawech-Fauceglia","year":"2006","unstructured":"Mhawech-Fauceglia P, Oberholzer M, Aschenafi S et al (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 130:374\u2013377","journal-title":"Arch Pathol Lab Med"},{"key":"2943_CR28","first-page":"e8387","volume":"12","author":"H Sharafi","year":"2012","unstructured":"Sharafi H, Pouryasin A, Alavian SM et al (2012) Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals. Hepat Mon 12:e8387","journal-title":"Hepat Mon"},{"key":"2943_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00251-013-0688-7","volume":"65","author":"JF Gelinas","year":"2013","unstructured":"Gelinas JF, Fabre T, Willems P et al (2013) IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics 65:397\u2013403","journal-title":"Immunogenetics"},{"key":"2943_CR30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djk030","volume":"99","author":"M Hisada","year":"2007","unstructured":"Hisada M, Chen BE, Jaffe ES et al (2007) Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 99:215\u2013222","journal-title":"J Natl Cancer Inst"},{"key":"2943_CR31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.2002.20.3.638","volume":"20","author":"M Federico","year":"2002","unstructured":"Federico M, Zinzani PL, Frassoldati A et al (2002) Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 20:638\u2013646","journal-title":"J Clin Oncol"},{"key":"2943_CR32","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al (2015) Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:1762\u20131769","journal-title":"Blood"},{"key":"2943_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11864-014-0285-5","volume":"15","author":"P Jain","year":"2014","unstructured":"Jain P, Pemmaraju N, Ravandi F (2014) Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options in Oncol 15:187\u2013209","journal-title":"Curr Treat Options in Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2943-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2943-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2943-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T12:02:52Z","timestamp":1658664172000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2943-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2943"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2943-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2017,2,18]]}}}